Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097916
Status:
COMPLETED
Last Update Posted:
2012-03-05
First Post:
2004-12-01
Brief Title:
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimers Disease
Sponsor:
Forest Laboratories
Organization:
Forest Laboratories
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
About 65 of patients with severe Alzheimers Disease AD will have symptoms of agitation There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimers Disease In a recent trial in the group of patients with moderate to severe AD treated with memantine there were fewer incidences of agitation It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimers Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None